Boothbay Fund Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Boothbay Fund Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,727	Closed	-$127K	–	2388
2021 Q3	$127K	Buy	40,727 +163	+0.4%	+$544	﹤0.01%	1751
2021 Q2	$151K	Buy	40,564 +4,671	+13%	+$15.5K	﹤0.01%	1623
2021 Q1	$124K	Buy	35,893 +18,717	+109%	+$76K	﹤0.01%	1454
2020 Q4	$58K	Buy	+17,176	New	+$61.5K	﹤0.01%	1192

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Boothbay Fund Management's PHAS Position: Q4 2021 in Review

Boothbay Fund Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 40,727 shares — an estimated $127K sold.

Boothbay Fund Management first reported a position in PHAS in Q4 2020 and held it in 4 quarters. The position peaked at $151K in Q2 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

Boothbay Fund Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Boothbay Fund Management sold 40,727 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $127K.
Boothbay Fund Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Boothbay Fund Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $151K in Q2 2021.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.